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ABSTRACT
Objective To measure knowledge and awareness of
human papillomavirus (HPV) testing in the USA, the UK
and Australia.
Methods Participants in the USA, UK and Australia
completed an anonymous web-based survey measuring
awareness and knowledge of HPV (n=2409). We report
analyses on a subsample of 1473 men and women in
the USA (n=617), UK (n=404) and Australia (n=452)
who had heard of HPV and completed questions about
HPV testing.
Results Overall, 50% of the sample (742/1473) had
heard of HPV testing. Awareness of HPV testing was
higher in the USA (62%) than in the UK (44%) and
Australia (40%) (p<0.001). Among those who had
heard of HPV testing, the mean knowledge score (out of
6) was 2.78 (SD: 1.49). No signiﬁcant differences in
knowledge score were found between the countries but,
overall, women scored signiﬁcantly higher than men
(2.96 vs 2.52, p<0.001).
Conclusions Awareness of HPV testing among people
who have heard of HPV is higher in the USA than in the
UK and Australia, but overall knowledge is low. This has
important implications in those countries where HPV
testing is being used in cervical screening. Increasing
knowledge about the implications of HPV test results
may help minimise any negative psychological
consequences associated with HPV testing. Raising
awareness in men could become increasingly important
if HPV testing is introduced into the management of
other cancers where HPV plays an aetiological role.
INTRODUCTION
Human papillomavirus (HPV) is a common sexu-
ally transmitted infection and a necessary agent in
the development of cervical cancer,1 with high-risk
HPV types 16 and 18 implicated in over 70% of
cervical cancer cases.2 Testing for high-risk types of
HPV is now being used within the cervical screen-
ing context around the world. It can be used as a
primary screening test and shows higher sensitivity
in detecting cervical abnormalities than cytology.3
Because of the high prevalence of transient infec-
tion in young women,4 primary HPV testing in the
USA is usually restricted to women aged 30 years
and over.5 Second, since 2001 in the USA6 and
2011 in England,7 HPV testing has been used to
triage borderline or mildly abnormal cytology
results, reducing the number of women on early
recall, and speeding up colposcopy follow-up for
those with high-risk HPV. Finally, it can be used as
a ‘test of cure’ following treatment. Women who
are HPV negative following treatment for cervical
abnormalities can safely be returned to routine
screening; this is now part of routine practice in
the UK and Australia.8–11
There is evidence that testing positive for HPV
in the cervical screening context can cause anxiety
and distress for some women.12–15 Those with a
positive HPV result at triage initially have worse
psychosocial outcomes than those managed by
repeat cytology.16 In the longer term, however, psy-
chosocial outcomes have been shown to be better
in women receiving HPV triage testing than
women receiving repeat cytology screening,16 and
levels of concern about the cytology result are
higher in those not tested for HPV at 6-month
follow-up.17 When informed of the advantages and
disadvantages of HPV testing and repeat cytology,
and when given the choice of management strat-
egies, women in Australia have shown a preference
for HPV testing.16 18
Communicating the meaning of HPV test results
and the purpose of HPV testing may help alleviate
anxiety, distress and concern, and reduce perceived
risk of cervical cancer which has been shown to be
much higher than actual risk.14 As HPV testing is
now being widely used in cervical screening, and may
be introduced in the context of other HPV-related
cancers in the future,19 assessing awareness and
knowledge of HPV testing is important to identify
information needs in women and men. Addressing
these needs could help women and men to under-
stand their results and minimise anxiety and distress
associated with HPV testing results.
We assessed knowledge about HPV testing across
three countries currently using the test in different
ways within cervical screening programmes, to see
how informed women and men in the general
population are, and to identify information gaps
overall and in demographic subgroups.
METHODS
Participants
A total of 12 259 participants were directed by
email to a web-based survey through international
online respondent panels in the USA, UK and
Australia managed by Survey Sampling
International (SSI). The target sample in each
country was 800 participants, with an even split of
men and women in the age range of 18–70 years.
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Men and women meeting the study criteria were randomly
selected and sent recruitment emails containing a link directing
them to the home page of our online survey which was entitled
‘What do you know about HPV?’ The survey was adapted for
use in the USA, UK and Australia, changing terminology where
appropriate. Further details of the sampling are available else-
where.20 21 Ethical approval was granted from research ethics
committees at Indiana University, USA, University College
London, UK and the University of Sydney, Australia.
Measures
Participants were given general information about the purpose
of the study and the contact details for the researchers in their
country of residence. The questionnaire initially asked partici-
pants their age, gender and country of residence to check that
the quota for their gender (n=400 men, n=400 women) or
country (n=800) was not already full. The ﬁrst question asked
‘Before today, had you ever heard of HPV?’ Participants who
responded ‘yes’ were directed to a further 15 questions that
assessed knowledge of HPV. Participants were then asked ‘Have
you ever heard of HPV testing?’ Those who responded ‘yes’
were directed to a further six questions that assessed knowledge
of HPV testing. The scale items can be seen in table 3. The
development and validation of the scale is described else-
where.21 Response options were true/false/don’t know, with
‘don’t know’ scored as incorrect. Participants additionally
answered demographic questions and indicated whether they
had received the HPV vaccination, and whether they had a
daughter aged 9–17 years (the HPV vaccination age-range).
Statistical analysis
To measure within-country demographic differences between
those who were and were not aware of HPV testing, independent
t tests were used for age, and χ2 tests were used for the categorical
demographic items: sex, relationship status, ethnicity, education,
having a daughter aged 9–17 and having had the HPV vaccine.
Multivariate logistic regression analyses were conducted to
explore independent demographic predictors of HPV testing
awareness overall and among men and women within each
country. The HPV testing knowledge scores for each country were
normally distributed, and so to examine the differences in mean
HPV testing knowledge score overall and among men and women
within each country, independent t tests were used for demo-
graphic variables with two groups, ANOVAs examined differences
with more than two groups, and posthoc Tukey’s tests were used
to establish where the signiﬁcant differences lay. All p values of
less than 0.05 were considered to be statistically signiﬁcant. χ2
tests were used to evaluate whether there were differences in the
proportion of correct responses to each of the individual
HPV-testing knowledge items between men and women overall
and within each country. Data were analysed using SPSS V.21.
RESULTS
Awareness of HPV testing
Overall, the survey was completed by 2409 men and women in
the USA, UK and Australia (see online supplementary ﬁgure S1).
Of these, 61% (1473/2409) had heard of HPV (USA: n=617,
UK: n=404, Australia: n=452). In the subsample who were
aware of HPV, 50% (742/1473) had heard of HPV testing
Table 1 Sample characteristics of those who had and had not heard of human papillomavirus (HPV) testing (n=1473)
USA UK AUS
Total heard
of HPV
(n=617)
Not aware of
HPV testing
(n=234)
Aware of
HPV testing
(n=383)
Total heard
of HPV
(n=404)
Not aware of
HPV testing
(n=227)
Aware of
HPV testing
(n=177)
Total heard
of HPV
(n=452)
Not aware of
HPV testing
(n=270)
Aware of
HPV testing
(n=182)
Age (mean (SD)) 45.12 (15.47) 48.30 (14.5) 43.17 (15.8)** 39.96 (14.17) 40.62 (14.35) 39.12 (13.94) 47.87 (14.73) 47.81 (14.94) 47.95 (14.46)
Sex (n (%))
Male 253 (41.0) 98 (41.9) 155 (40.5) 155 (38.4) 88 (38.8) 67 (37.9) 164 (36.6) 87 (32.2) 77 (42.3)*
Female 364 (59.0) 136 (58.1) 228 (59.5) 249 (61.6) 139 (61.2) 110 (62.1) 288 (63.7) 183 (67.8) 105 (57.7)
Relationship status (n (%))
Single 201 (32.6) 73 (31.2) 128 (33.4) 128 (31.7) 71 (31.3) 57 (32.2) 120 (26.5) 60 (22.2) 60 (33.0)
Dating 51 (8.3) 15 (6.4) 36 (9.4) 43 (10.6) 24 (10.6) 19 (9.7) 34 (7.5) 24 (8.9) 10 (5.5)
Cohabiting 50 (8.1) 19 (8.1) 31 (8.1) 69 (17.1) 40 (17.6) 29 (16.4) 67 (14.8) 44 (16.3) 23 (12.6)
Married 315 (51.1) 127 (54.3) 188 (49.1) 164 (40.6) 92 (40.5) 72 (40.7) 231 (51.1) 142 (52.6) 89 (48.9)
Ethnicity† (n (%))
Majority 527 (85.4) 199 (85.0) 328 (85.6) 332 (82.2) 196 (86.3) 136 (76.8)* 347 (76.8) 215 (79.6) 132 (72.5)
Minority 90 (14.6) 35 (15.0) 55 (14.4) 72 (17.8) 31 (13.7) 41 (23.2) 105 (23.2) 55 (20.4) 50 (27.5)
Education‡ (n (%))
High 248 (40.2) 80 (34.2) 168 (43.9)* 178 (44.2) 96 (42.3) 82 (46.3) 120 (26.5) 58 (21.5) 62 (34.1)*
Medium 227 (36.8) 84 (35.9) 143 (37.3) 149 (37.0) 82 (36.1) 67 (37.9) 165 (36.5) 103 (38.1) 62 (34.1)
Low 142 (23.0) 70 (29.9) 72 (18.8) 76 (18.9) 48 (21.1) 28 (15.8) 167 (36.9) 109 (40.4) 58 (31.8)
Daughter
9–17 years
85 (13.8) 36 (15.3) 49 (12.8) 72 (17.9) 48 (21.1) 24 (13.6) 75 (16.6) 35 (13.0) 40 (22.1)*
Had HPV
vaccine§
43 (11.8) 11 (8.1) 32 (14.0) 21 (8.4) 9 (6.5) 12 (10.9) 43 (14.9) 30 (16.4) 13 (12.4)
*Significant at p<0.05.
**Significant at p<0.001.
†Majority in USA=white non-hispanic, UK=white British, AUS=Australian.
‡Education was coded as follows:
High: college graduate/graduate school (USA), degree/postgraduate degree (UK), any university education (AUS). Medium: some college/associate degree (USA), vocational/A-levels/other
qualification<degree (UK), vocational qualification (AUS). Low: high school, Continuing Education Diploma or below (USA); no formal education/GCSEs (UK); no formal education/high
school (AUS).
§Women only.
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(USA: n=383, UK: n=177, Australia: n=182). Awareness of
HPV testing was higher in the USA (62%) than the UK
(44%) and Australia (40%) (χ2(2)=59.22, p<0.001). We
examined associations between demographic variables and
awareness of HPV testing within each country (table 1). In
the USA, awareness of HPV testing was associated with higher
educational level: 44% of those aware of testing were in the
high (college graduate or above) education group, compared
with 34% of those who were unaware (χ2(2)=11.26,
p=0.004). There was also a signiﬁcant association between
HPV testing awareness and education level in Australia, with
34% of those having heard of HPV testing being in the high
(any university education) education group compared with
22% of those who were unaware (χ2(2)=9.11, p=0.011). In
the UK, there was no association with education. Participants
aware of HPV testing in the USA were signiﬁcantly younger
than those not aware: mean age was 43 years and 48 years
respectively (t(524.1)=4.13, p<0.001). In Australia, there was
a signiﬁcant relationship between awareness of HPV testing
and gender, with a higher proportion of respondents aware of
HPV testing being men (42%) compared with those not
aware of HPV testing (32%) (χ2(1)=4.78, p=0.029).
Respondents in Australia who had heard of HPV testing were
more likely to have a daughter in the vaccine age-range than
those who had not (22% vs 13%) (χ2(1)=6.52, p=0.011). In
the UK, there was a higher proportion of ethnic minority
respondents in the group that was aware of HPV testing
(23%) compared with the group that was unaware (14%)
(χ2(1)=5.51, p=0.019). Demographic variables showing
bivariate associations with awareness of HPV testing were
entered into multivariate logistic regression analyses (one for
each country) (see table 2).
In subgroup analyses among men and women, some gender
differences in the predictors of HPV testing awareness emerged.
In US women, awareness of HPV testing was signiﬁcantly lower
in the least educated group (OR=0.46, 95% CI 0.27 to 0.80)
and in the group that had a daughter in the vaccination age
range (OR=0.48, 95% CI 0.25 to 0.90). Among Australian
women, having a daughter in the vaccination age range was a
signiﬁcant predictor of HPV testing awareness (OR=2.16, 95%
CI 1.12 to 4.18). Among Australian men, being from an ethnic
minority group was a signiﬁcant predictor of HPV testing
awareness (OR=2.17, 95% CI 1.04 to 4.54). There were no
gender differences in demographic predictors of HPV testing
awareness in the UK.
Responses to individual HPV testing items
The proportion of respondents giving the correct answer to
each individual item is shown in table 3, with statistical tests and
p values. Across all three countries, there was highest awareness
of the fact that a HPV positive result does not mean a woman
will deﬁnitely develop cervical cancer (76% correct overall),
although respondents in Australia were less likely to answer this
item correctly than those in the USA and UK (65% Australia vs
79% USA vs 79% UK; χ2(2)=15.22, p<0.001). There was also
high awareness that a HPV test can be carried out at the same
time as a Pap test (74% correct overall). The other four items
were answered correctly by fewer than half the respondents,
with lowest awareness of the low-risk implications of a HPV
negative result (24% correct overall). In the UK, men were
more likely than women to correctly answer the item that a
negative HPV result means a woman’s risk of cervical cancer is
low (42% men correct vs 24% women). In Australia, women
were more likely than men to know that you do not get the
results the same day when you have a HPV test (42% women vs
25% men).
Knowledge of HPV testing (total scale score)
Among those who had heard of HPV testing, the mean knowl-
edge score (out of 6) was 2.78 (SD: 1.49). There were no sig-
niﬁcant differences in knowledge score between countries (mean
scores were 2.83 in the USA; 2.91 in the UK; and 2.57 in
Australia). Overall, women scored signiﬁcantly higher than men
(2.96 vs 2.52, t(740)=−3.998, p<0.001).
Table 2 Demographic correlates of awareness of human papillomavirus (HPV) testing (multivariate logistic regression models)
OR (95% CI)
USA (n=617) UK (n=404) AUS (n=451)
Age 0.98 (0.97 to 0.99)*** – –
Relationship status
Single – – 1.73 (1.10 to 2.74)*
Dating/cohabiting – – 0.79 (0.48 to 1.32)
Married (reference) – – 1.00
Ethnicity†
Majority (reference) – 1.00 –
Minority – 1.91 (1.14 to 3.19)* –
Education‡
High (reference) 1.00 – 1.00
Medium 0.83 (0.57 to 1.22) – 0.57 (0.35 to 0.92)*
Low 0.49 (0.32 to 0.74)*** – 0.53 (0.33 to 0.87)**
Have a daughter 9–17 years – – 1.99 (1.19 to 3.34)**
*p<0.05.
**p<0.01.
***p<0.001.
†Majority in USA=white non-hispanic, UK=white British, AUS=Australian.
‡Education was coded as follows:
High: college graduate/graduate school (USA); degree/postgraduate degree (UK), any university education (AUS). Medium: some college/associate degree (USA); vocational/A-levels/other
qualification<degree (UK); vocational qualification (AUS). Low: high school, CED or below (USA); no formal education/GCSEs (UK); no formal education/high school (AUS).
Dodd RH, et al. Sex Transm Infect 2014;90:201–207. doi:10.1136/sextrans-2013-051402 203
Health services research
 group.bmj.com on July 16, 2014 - Published by sti.bmj.comDownloaded from 
We assessed demographic predictors of higher knowledge
scores within each country (see table 4 for statistical tests and p
values). Women had signiﬁcantly higher scores than men in the
USA (mean=3.07 for women vs 2.47 for men) and Australia
(mean=2.77 for women vs 2.30 for men), but there was no
gender difference in the UK. In Australia, respondents who were
cohabiting (mean=3.35) had signiﬁcantly higher scores than
those who were married (mean=2.40), and women who had
received the HPV vaccination (mean=4.08) had signiﬁcantly
higher scores than those who had not (mean=2.59). Knowledge
also showed signiﬁcant associations with education in the USA
and the UK, though the pattern of association was not
consistent.
In subgroup analyses among men and women, some gender
differences in the predictors of HPV testing knowledge
emerged. Educational level was signiﬁcantly associated with
HPV testing knowledge among women in the USA (F(2,225)
=3.49, p=0.03) but not men, with posthoc analysis showing
the difference lay between high and low educational levels
(mean=3.27 vs 2.61, p=0.02). Relationship status had a signiﬁ-
cant association with HPV testing knowledge in Australian
women (F(2,102)=4.32, p=0.02) but not men, with posthoc
analysis showing women who were cohabiting were more
knowledgeable about HPV testing than married women
(mean=3.67 vs 2.44, p=0.04). There were no other signiﬁcant
gender differences in associations between demographic vari-
ables and HPV testing knowledge.
DISCUSSION
This study uses a validated measure to assess awareness and
knowledge of HPV testing across three countries. Around half
of those who had heard of HPV had also heard of HPV testing,
demonstrating that awareness of HPV does not imply knowl-
edge of HPV testing. A higher proportion of the sample from
the USA had heard of HPV testing compared to the UK and
Australia, but this did not translate to greater knowledge about
HPV testing. Signiﬁcant demographic predictors of awareness of
HPV testing were younger age and higher education in the USA,
being of an ethnic minority group in the UK, and being single,
having more education and having a daughter in the HPV vac-
cination age range in Australia. The education results in the USA
and Australia were consistent with previous studies measuring
awareness of HPV.22 In all three countries, women had higher
HPV testing knowledge than men. This would be expected
since HPV is commonly associated with cervical cancer, so it is
women who are currently referred for HPV testing in the coun-
tries included in our study. Previous research on the psycho-
logical implications of HPV testing has also focused on
women.12 13 16 18
The two knowledge items that were consistently answered
correctly by the majority of participants across the three coun-
tries were that the HPV test can be done at the same time as a
Pap test, and that testing positive for HPV does not mean a
woman will deﬁnitely get cervical cancer, demonstrating some
understanding of the implications of HPV test results. However,
men and women in all three countries had limited knowledge
that: HPV testing is not used to indicate that the HPV vaccine is
needed, and if a HPV test shows a woman does not have HPV,
that her risk of cervical cancer is low. This corresponds with
previous ﬁndings that a negative HPV test result is no more
reassuring than no HPV test in women with abnormal cytology
results,14 as women do not understand the implications of the
results. This demonstrates where knowledge could be improved,
and points to aspects of HPV testing information that could be
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targeted in educational materials. It also suggests that partici-
pants seem to be able to interpret the meaning of a positive test
result more easily than a negative test result. In the USA, clini-
cians have been shown to use HPV testing in ways which
deviate from the guidelines.23 Agreement of how and when
HPV testing should be offered, and the key educational mes-
sages needed about HPV testing, could be useful to ensure that
the information people receive is consistent across sources and
congruent with procedures. Interestingly, UK men had higher
levels of understanding of the implications of a negative HPV
test than women, which may be explained by women’s experi-
ences of uncertainty and confusion about the virus translating to
a misunderstanding about their results.24 There were greater dif-
ferences in knowledge between US men and women than in the
UK and Australia, with US women correctly answering more
knowledge items than men. Lower knowledge in Australia may
reﬂect the limited use of HPV testing in comparison to use of
HPV testing in the USA and UK.
Australian respondents who had a daughter in the HPV vac-
cination age range were more likely to have heard of HPV
testing than those without a daughter in the HPV vaccination
age range. This may be a consequence of parents searching for
more information to make an informed decision about vaccinat-
ing their daughter, in line with ﬁndings from a systematic review
of parental knowledge of the HPV vaccination.25 When stratify-
ing by gender, the association between having heard of HPV
testing and having a daughter in the vaccination age group was
signiﬁcant for women and not men, perhaps reﬂecting the ‘fem-
inisation of HPV’26 and the predominantly maternal role in
childhood vaccination decisions. Surprisingly, the relationship
between having a daughter in the HPV vaccination age range
and awareness of HPV testing was not found in the UK, where
school-aged girls are also being vaccinated. One possible explan-
ation for this difference from the Australian ﬁnding is that the
information campaign in the UK promotes the ‘cervical cancer
vaccine’, whereas the Australian information materials call it the
‘HPV school vaccination programme’. This may make it harder
for women in the UK to understand the link between the HPV
vaccine and HPV testing within the screening programme.
There is a need to address this knowledge gap in men and
women. In the USA, women with a daughter aged 9–17 were
less likely to have heard about HPV testing than women
without a daughter in the vaccine age range. As there is not a
school-based HPV vaccination programme in the USA unlike in
the UK and Australia, there may be limited awareness of HPV
testing in this subgroup.
Across all UK respondents and in Australian males, those
from an ethnic minority group were more likely to be aware of
HPV testing, contrasting with ﬁndings of awareness of HPV
from previous literature.27 28 This may reﬂect our use of a web-
based survey and may not translate into clinically signiﬁcant
ﬁndings. A similarly surprising ﬁnding was the higher awareness
of HPV testing in men than women in Australia, although
women were more likely to have heard of HPV. Additionally, a
greater number of Australian males with higher educational
levels had heard of HPV testing than the equivalent group for
women. This may be due to men preferring to indicate that they
have heard of HPV testing rather than admitting that they have
not, corroborating previous research ﬁnding men to overesti-
mate their performance in knowledge tests.29 This would also
be consistent with our ﬁnding that women were more knowl-
edgeable than men on the knowledge scale for HPV testing,
despite their lower self-reported awareness levels.
The differing levels of knowledge and awareness of HPV
testing highlights the need for targeted awareness strategies in
those countries where HPV testing is now being implemented.
Knowledge and awareness could be improved through ensuring
that information is accessible to those with lower education
levels, for example, through not limiting information to written
materials, encouraging discussion about HPV testing in the
media and incorporating information about HPV and the impli-
cations of HPV test results in community outreach initiatives.
Table 4 Demographic differences in mean human papillomavirus (HPV) testing knowledge
USA (n=383) UK (n=177) AUS (n=182)
n
HPV testing
knowledge
(mean (SD))
Significance
(p value) n
HPV testing
knowledge
(mean (SD))
Significance
(p value) n
HPV testing
knowledge
(mean (SD))
Significance
(p value)
Sex (mean (SD))
Male 155 2.47 (1.50) t(381)=−3.97, (<0.001) 67 2.90 (1.38) NS 77 2.30 (1.51) t(180)=−2.01, (0.046)
Female 228 3.07 (1.41) 110 2.92 (1.39) 105 2.77 (1.61)
Relationship status (mean)
Single 128 2.66 (1.51) NS 57 3.02 (1.49) NS 60 2.37 (1.68) F(3,178)=3.84, (0.011)
Dating 36 2.67 (1.72) 19 3.00 (1.45) 10 3.50 (1.43)
Cohabiting 31 3.35 (1.40) 29 3.07 (1.25) 23 3.35 (1.50)*
Married 188 2.89 (1.40) 72 2.74 (1.33) 89 2.40 (1.48)*
Education (mean)
High 168 3.00 (1.54)* F(2,380)=3.80, (0.023) 82 3.12 (1.30)* F(2,174)=3.11, (0.047) 62 2.77 (1.59) NS
Medium 143 2.83 (1.43) 67 2.58 (1.48)* 62 2.63 (1.60)
Low 72 2.43 (1.34)* 28 3.07 (1.27) 58 2.29 (1.53)
Had HPV vaccine (mean (SD))
Yes 32 3.31 (1.62) NS 12 2.75 (1.06) NS 13 4.08 (1.55) t(103)=3.27, (<0.001)
No 96 3.03 (1.38) 98 2.94 (1.43) 92 2.59 (1.54)
*Represents significant differences at p<0.05 in posthoc Tukey’s tests.
NB, only demographic items with significant differences are shown in the table.
NS, not significant, that is, p>0.05.
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This could help reduce the anxiety and distress in women fol-
lowing HPV testing.12–14 Women need to be aware of the impli-
cations of the results of HPV testing and what this may mean
for future treatment. Offering an educational intervention has
been shown to reduce concern in women testing positive for
HPV.30 Men also need to be made more aware of HPV testing
as this is being recommended as part of the clinical management
of HPV-related non-cervical cancers (eg, oropharyngeal squa-
mous cell carcinoma)19 and some clinicians in the USA are
already providing ‘off-label’ HPV testing for men.31
By recruiting online, we were able to directly compare
samples across the three countries using a validated measure of
HPV testing knowledge,21 which allows for comparison in
future studies. The use of quotas ensured that respondents with
lower levels of education were well represented. The sample was
limited to three countries, and participants were recruited from
online panels with set quota sampling methods, and so may not
be representative of the population. Caution should also be
exercised in generalising these results to other countries.
Additionally, only those who had heard of HPV were included
in our analyses, so some of the demographic associations may
not generalise to the wider population. For example, although
awareness of HPV testing was higher in Australian men than
women in our sample, this could be misleading as more
Australian women are aware of HPV itself.20 The sample was
drawn from internet users which may have introduced some
bias.
It is important that people understand why they are being
offered HPV testing and what the test results mean. Our study
provides an indication of current knowledge about HPV testing
and understanding of test results in three countries where HPV
testing is being used for different purposes. Our ﬁndings could
be used to inform the development of information materials to
accompany HPV testing in cervical screening programmes.
Key messages
▸ Overall knowledge of human papillomavirus (HPV) testing is
low in the USA, the UK and Australia.
▸ Targeted knowledge and awareness strategies are needed in
countries where HPV testing is being implemented.
▸ Increasing understanding around the implications of a
negative HPV test result may help minimise any negative
psychological consequences associated with the test.
▸ Men need to be made more aware of HPV testing as it may
be introduced into management of other HPV-related
cancers.
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